ArticleBMC cancer2026
A cohort study investigating differences in skeletal muscle mitochondrial function between prostate cancer patients and healthy controls.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThere has been an increasing prevalence of prostate cancer worldwide, and therefore a growing clinical need to understand and maintain whole body health in this cohort. There is currently limited evidence of the underlying physiology which leads to certain patients developing cancer cachexia. Based on pre-clinical evidence, skeletal muscle (SKM) mitochondria are suspected to play an integral role, however to date, there is little human data to support this. This study compares SKM mitochondrial oxidative phosphorylation (OXPHOS) in prostate cancer patients due to undergo treatment with curative intent to healthy volunteers, with a hypothesis that this would be lower in the cancer cohort.
methodsTwelve prostate cancer patients and 8 disease-free males matched for age and body mass index (BMI) were recruited to this study. All participants completed assessments of physical function using clinically recognised tools (handgrip strength, timed up-and-go, and short physical performace battery) and muscle architecture via ultrasound. All participants also had a SKM (vastus lateralis) biopsy collected. Using a high-resolution respirometer (OROBOROS) and standardised substrate uncoupled inhibitor titration (SUIT) protocol, SKM OXPHOS was assessed, with the biopsy also analysed for citrate synthase activity and gene expression via RT-PCR.
resultsDespite our groups being well-matched in terms of age and BMI, and there being no differences in SKM physical function or architecture, extrinsic OXPHOS was significantly lower in the prostate cancer cohort compared to healthy controls (maximal complex I activity: 47.1 ± 19.7 vs. 27.1 ± 12.1, p = 0.01; maximal complex I + II activity: 74.8 ± 26.7 vs. 50.7 ± 13.4, p = 0.01; maximal activity: healthy: 95.9 ± 37.4 vs. 62.1 ± 16.3, p = 0.02). The same was true for Respiratory Control Ratio (2.7 ± 0.9 vs. 1.8 ± 0.9, p = 0.04). There was no difference in intrinsic OXPHOS between the groups.
conclusionThis study found lower SKM extrinsic OXPHOS in those with prostate cancer, in the absence of muscle mass or functional loss, when compared to age-matched disease-free volunteers. This appears to be due to changes in mitochondrial content or remodelling, with preservation of intrinsic function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.